Effect of switching from pioglitazone to the sodium glucose co-transporter-2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type 2 diabetes mellitus : An open-label, prospective, randomized, parallel-group comparison trial

Cho, Kyu Yong; Nakamura, Akinobu; Omori, Kazuno et al.

Diabetes, Obesity and Metabolism, 2019, 21(3), 710-714

Permalink : https://hdl.handle.net/2115/72905

このアイテムのアクセス数:1,025件（2026-08-24 21:40 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
m13557-sup-0004-tables1 docx 13.9 KB 206 Supporting Information: Table S1
m13557-sup-0003-appendixs3 docx 11.9 KB 203 Supporting Information: Supplemental Figure Legends
m13557-sup-0002-appendixs2 docx 14.0 KB 219 Supporting Information: Appendix S2
m13557-sup-0001-appendixs1 docx 14.4 KB 208 Supporting Information: Appendix S1
Cho_et_al-2019-Diabetes,_Obesity_and_Metabolism pdf 483 KB 600
dom13557-sup-0003-appendixs3-2 pptx 62.4 KB 235 Supporting Information: Supplemental Figures

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
open access
URI
https://hdl.handle.net/2115/72905
タイトル
Effect of switching from pioglitazone to the sodium glucose co-transporter-2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type 2 diabetes mellitus : An open-label, prospective, randomized, parallel-group comparison trial
著者
Cho, Kyu Yong ; Nakamura, Akinobu ; Omori, Kazuno ; Takase, Takahiro ; Miya, Aika ; Manda, Naoki ; Kurihara, Yoshio ; Aoki, Shin ; Atsumi, Tatsuya ; Miyoshi, Hideaki
著者名
Cho, Kyu Yong
e-Rad_Researcher
70552420
著者名
Nakamura, Akinobu
著者名
Omori, Kazuno
著者名
Takase, Takahiro
著者名
Miya, Aika
著者名
Manda, Naoki
著者名
Kurihara, Yoshio
著者名
Aoki, Shin
e-Rad_Researcher
20301905
著者名
Atsumi, Tatsuya
e-Rad_Researcher
30360902
著者名
Miyoshi, Hideaki
言語
英語
キーワード
body weight control
cardiovascular disease
randomized trial
SGLT2 inhibitor
thiazolidinediones
type 2 diabetes
発行日
2019-03
出版者
Wiley
収録物名
Diabetes, Obesity and Metabolism
巻(号)
21(3)
ページ
710-714
抄録
The effects of dapagliflozin (DAP) and pioglitazone (PIO) on body weight and glycaemic control were compared in patients with type 2 diabetes mellitus. Seventy-one patients on PIO were either switched to DAP (n = 36) at 5 mg per day or continued on PIO (n = 35). Primary endpoints were superiority of body weight loss and non-inferiority of HbA1c level after 24 weeks with DAP. Body weight decrease was greater with DAP than with PIO (75.3 ± 14.9 to 71.3 ± 15.1 kg vs. 74.7 ± 13.8 to 75.2 ± 13.9 kg; P < 0.01). Change in the HbA1c level was comparable (P = 0.64). The level of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and urinary albumin : creatinine ratio (ACR) decreased only with DAP (NT-proBNP, P < 0.01; ACR, P = 0.02), and the change in NT-proBNP correlated negatively with baseline NT-proBNP level (ρ = -0.68, P < 0.01) and log-converted ACR (ρ = -0.35, P < 0.05). DAP promotes body weight loss in type 2 diabetes mellitus and may decrease fluid retention, thus reducing the occurrence of cardiovascular events.
資源タイプ
学術雑誌論文
出版タイプ
Version of Record
権利情報
Creative Commons Attribution-NonCommercial 4.0 International
PISSN
1462-8902
関連情報 (isIdenticalTo)
出版社版DOI
https://doi.org/10.1111/dom.13557